Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 2/2011

01-02-2011 | Original Article

Schedule treatment design and quantitative in vitro evaluation of chemotherapeutic combinations for metastatic prostate cancer therapy

Authors: Ana Catarina Pinto, Susana Ângelo, João Nuno Moreira, Sérgio Simões

Published in: Cancer Chemotherapy and Pharmacology | Issue 2/2011

Login to get access

Abstract

Purpose

Preclinical evaluation is essential for a rational design of combination chemotherapy as some agents, with known mechanisms of action and non-overlapping toxicities may increase the therapeutic index of anticancer drugs, whose clinical success is hindered by side effects and drug resistance. The present study investigated new drug combinations with potential outcome for the treatment of metastatic prostate cancer. This final clinical stage exhibits predominantly hormone-refractory prostate cancer (HRPC) cells but also a minority of hormone responsive cells.

Methods

Growth inhibition activity of simultaneous and sequential combinations was evaluated by resazurin assay. In vitro evaluation of synergism, additivity, or antagonism, against prostate cancer cell lines, was performed by the median effect analysis. The importance of dosage, exposure time, drug ratio, and type of treatment were investigated and compared.

Results

Most simultaneous combinations of two drugs with different mechanisms of action or of two topoisomerase II inhibitors resulted in mild antagonism of antiproliferative effects, particularly notorious at high cell death. Imatinib–mitoxantrone and ciprofloxacin–etoposide combinations were exceptions, as they yielded additivity and dose reduction index (DRI) values of 2.6 and 3.5-fold for mitoxantrone and etoposide, respectively. Sequential combinations (ciprofloxacin or imatinib pre-treatment) revealed additive growth inhibition effects, translated in much higher DRI values (from 7.0 to 15.3-fold). Moderate synergism was restricted to sequential ciprofloxacin combinations at high cell death.

Conclusions

Ciprofloxacin and imatinib significantly improve growth inhibition activity of standard antineoplastic drugs in a schedule-dependent manner and, therefore, may have an important role as adjuvant therapeutic agents in a clinical setting.
Literature
1.
Goodin S, Rao KV, DiPaola RS (2002) State-of-the-art treatment of metastatic hormone-refractory prostate cancer. Oncologist 7:360–370CrossRefPubMed
2.
Sonpavde G, Hutson TE, Berry WR (2006) Hormone refractory prostate cancer: management and advances. Cancer Treat Rev 32:90–100CrossRefPubMed
3.
Di Lorenzo G, Autorino R, De Laurentiis M, Bianco R, Lauria R, Giordano A, De Sio M, D’Armiento M, Bianco AR, De Placido S (2003) Is there a standard chemotherapeutic regimen for hormone-refractory prostate cancer? Present and future approaches in the management of the disease. Tumori 89:349–360PubMed
4.
Kamat AM, DeHaven JI, Lamm DL (1999) Quinolone antibiotics: a potential adjunct to intravesical chemotherapy for bladder cancer. Urology 54:56–61CrossRefPubMed
5.
El-Rayes BF, Grignon R, Aslam N, Aranha O, Sarkar FH (2002) Ciprofloxacin inhibits cell growth and synergises the effect of etoposide in hormone resistant prostate cancer cells. Int J Oncol 21:207–211PubMed
6.
Aranha O, Grignon R, Fernandes N, McDonnell TJ, Wood DP Jr, Sarkar FH (2003) Suppression of human prostate cancer cell growth by ciprofloxacin is associated with cell cycle arrest and apoptosis. Int J Oncol 22:787–794PubMed
7.
Hubert A, Lyass O, Pode D, Gabizon A (2000) Doxil (Caelyx): an exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer. Anticancer Drugs 11:123–127CrossRefPubMed
8.
9.
Hande KR (1998) Etoposide: four decades of development of a topoisomerase II inhibitor. Eur J Cancer 34:1514–1521CrossRefPubMed
10.
11.
Vlahovic G, Ponce AM, Rabbani Z, Salahuddin FK, Zgonjanin L, Spasojevic I, Vujaskovic Z, Dewhirst MW (2007) Treatment with imatinib improves drug delivery and efficacy in NSCLC xenografts. Br J Cancer 97:735–740CrossRefPubMed
12.
Rao K, Goodin S, Levitt MJ, Dave N, Shih WJ, Lin Y, Capanna T, Doyle-Lindrud S, Juvidian P, DiPaola RS (2005) A phase II trial of imatinib mesylate in patients with prostate specific antigen progression after local therapy for prostate cancer. Prostate 62:115–122CrossRefPubMed
13.
Hande KR (1998) Clinical applications of anticancer drugs targeted to topoisomerase II. Biochim Biophys Acta 1400:173–184PubMed
14.
Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CM, Murphy KC (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14:1756–1764PubMed
15.
Zhou XJ, Rahmani R (1992) Preclinical and clinical pharmacology of vinca alkaloids. Drugs 44(Suppl 4):1–16 (discussion 66–19)CrossRefPubMed
16.
Hardman JG, Limbird LE, Gilman AG (2001) Goodman LSPbot: Goodman & Gilman’s the pharmacological basis of therapeutics. In: Hardman JG, Limbird LE (eds)/Alfred Goodman Gilman (consulting ed) 10th edn. McGraw-Hill, New York, London
17.
Pinto AC, Moreira JN, Simoes S (2009) Ciprofloxacin sensitizes hormone-refractory prostate cancer cell lines to doxorubicin and docetaxel treatment on a schedule-dependent manner. Cancer Chemother Pharmacol 64:445–454CrossRefPubMed
18.
Chou TC, Talalay P (1983) Analysis of combined drug effects: a new look at a very old problem. Trends Pharmacol Sci 4:450–454CrossRef
19.
Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27–55CrossRefPubMed
20.
Chou TC (1994) Assessment of synergistic and antagonistic effects of chemotherapeutic agents in vitro. Contrib Gynecol Obstet 19:91–107PubMed
21.
Budman DR, Calabro A, Kreis W (2002) Synergistic and antagonistic combinations of drugs in human prostate cancer cell lines in vitro. Anticancer Drugs 13:1011–1016CrossRefPubMed
22.
Chou TC, Tan QH, Sirotnak FM (1993) Quantitation of the synergistic interaction of edatrexate and cisplatin in vitro. Cancer Chemother Pharmacol 31:259–264CrossRefPubMed
23.
Kreis W, Budman DR, Calabro A (2001) A reexamination of PSC 833 (Valspodar) as a cytotoxic agent and in combination with anticancer agents. Cancer Chemother Pharmacol 47:78–82CrossRefPubMed
24.
Wampler GL, Carter WH Jr, Campbell ED, Keefe PA (1992) Relationships between various uses of antineoplastic drug-interaction terms. Cancer Chemother Pharmacol 31:111–117CrossRefPubMed
25.
Capranico G, Binaschi M, Borgnetto ME, Zunino F, Palumbo M (1997) A protein-mediated mechanism for the DNA sequence-specific action of topoisomerase II poisons. Trends Pharmacol Sci 18:323–329PubMed
26.
Elsea SH, Westergaard M, Burden DA, Lomenick JP, Osheroff N (1997) Quinolones share a common interaction domain on topoisomerase II with other DNA cleavage-enhancing antineoplastic drugs. Biochemistry 36:2919–2924CrossRefPubMed
27.
Bakshi RP, Galande S, Muniyappa K (2001) Functional and regulatory characteristics of eukaryotic type II DNA topoisomerase. Crit Rev Biochem Mol Biol 36:1–37CrossRefPubMed
28.
29.
van Brussel JP, van Steenbrugge GJ, Romijn JC, Schroder FH, Mickisch GH (1999) Chemosensitivity of prostate cancer cell lines and expression of multidrug resistance-related proteins. Eur J Cancer 35:664–671CrossRefPubMed
30.
Barrett JF, Gootz TD, McGuirk PR, Farrell CA, Sokolowski SA (1989) Use of in vitro topoisomerase II assays for studying quinolone antibacterial agents. Antimicrob Agents Chemother 33:1697–1703PubMed
31.
Anderson VE, Zaniewski RP, Kaczmarek FS, Gootz TD, Osheroff N (1999) Quinolones inhibit DNA religation mediated by Staphylococcus aureus topoisomerase IV. Changes in drug mechanism across evolutionary boundaries. J Biol Chem 274:35927–35932CrossRefPubMed
32.
Bromberg KD, Burgin AB, Osheroff N (2003) A two-drug model for etoposide action against human topoisomerase IIalpha. J Biol Chem 278:7406–7412CrossRefPubMed
33.
Liu WM, Joel SP (2003) The schedule-dependent effects of etoposide in leukaemic cell lines: a function of concentration and duration. Cancer Chemother Pharmacol 51:291–296CrossRefPubMed
34.
Bromberg KD, Burgin AB, Osheroff N (2003) Quinolone action against human topoisomerase IIalpha: stimulation of enzyme-mediated double-stranded DNA cleavage. Biochemistry 42:3393–3398CrossRefPubMed
35.
Boland MP, Fitzgerald KA, O’Neill LA (2000) Topoisomerase II is required for mitoxantrone to signal nuclear factor kappa B activation in HL60 cells. J Biol Chem 275:25231–25238CrossRefPubMed
36.
Leroy D, Kajava AV, Frei C, Gasser SM (2001) Analysis of etoposide binding to subdomains of human DNA topoisomerase II alpha in the absence of DNA. Biochemistry 40:1624–1634CrossRefPubMed
37.
Buchdunger E, O’Reilly T, Wood J (2002) Pharmacology of imatinib (STI571). Eur J Cancer 38(Suppl 5):28–36CrossRef
38.
Kubler HR, van Randenborgh H, Treiber U, Wutzler S, Battistel C, Lehmer A, Wagenpfeil S, Hartung R, Paul R (2005) In vitro cytotoxic effects of imatinib in combination with anticancer drugs in human prostate cancer cell lines. Prostate 63:385–394CrossRefPubMed
39.
Ostman A, Heldin CH (2007) PDGF receptors as targets in tumor treatment. Adv Cancer Res 97:247–274CrossRefPubMed
40.
Peng B, Lloyd P, Schran H (2005) Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 44:879–894CrossRefPubMed
41.
42.
Gewirtz DA (1999) A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57:727–741CrossRefPubMed
43.
Hande KR, Wedlund PJ, Noone RM, Wilkinson GR, Greco FA, Wolff SN (1984) Pharmacokinetics of high-dose etoposide (VP-16–213) administered to cancer patients. Cancer Res 44:379–382PubMed
44.
Ehninger G, Schuler U, Proksch B, Zeller KP, Blanz J (1990) Pharmacokinetics and metabolism of mitoxantrone. A review. Clin Pharmacokinet 18:365–380CrossRefPubMed
45.
Peng B, Dutreix C, Mehring G, Hayes MJ, Ben-Am M, Seiberling M, Pokorny R, Capdeville R, Lloyd P (2004) Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion. J Clin Pharmacol 44:158–162CrossRefPubMed
46.
Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031–1037CrossRefPubMed
47.
Naber KG, Sorgel F, Kees F, Jaehde U, Schumacher H (1989) Pharmacokinetics of ciprofloxacin in young (healthy volunteers) and elderly patients, and concentrations in prostatic fluid, seminal fluid, and prostatic adenoma tissue following intravenous administration. Am J Med 87:57S–59SCrossRefPubMed
48.
Gonzalez MA, Uribe F, Moisen SD, Fuster AP, Selen A, Welling PG, Painter B (1984) Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers. Antimicrob Agents Chemother 26:741–744PubMed
Metadata
Title
Schedule treatment design and quantitative in vitro evaluation of chemotherapeutic combinations for metastatic prostate cancer therapy
Authors
Ana Catarina Pinto
Susana Ângelo
João Nuno Moreira
Sérgio Simões
Publication date
01-02-2011
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 2/2011
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-010-1315-z

Other articles of this Issue 2/2011

Cancer Chemotherapy and Pharmacology 2/2011 Go to the issue

Original Article

Plasma pharmacokinetics and oral bioavailability of the 3,4,5,6-tetrahydrouridine (THU) prodrug, triacetyl-THU (taTHU), in mice

Original Article

Tamoxifen and raloxifene suppress the proliferation of estrogen receptor-negative cells through inhibition of glutamine uptake

Original Article

A novel bis-indole destabilizes microtubules and displays potent in vitro and in vivo antitumor activity in prostate cancer

Original Article

Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer

Original Article

Combination effects of platinum drugs and N 1, N 11 diethylnorspermine on spermidine/spermine N 1-acetyltransferase, polyamines and growth inhibition in A2780 human ovarian carcinoma cells and their oxaliplatin and cisplatin-resistant variants

Original Article

Pharmacokinetics in mice and metabolism in murine and human liver fractions of the putative cancer chemopreventive agents 3′,4′,5′,5,7-pentamethoxyflavone and tricin (4′,5,7-trihydroxy-3′,5′-dimethoxyflavone)
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits